Description:

Size: 100ul

Catalog no.: bs-1684R-A594

Price: 380 EUR

Product details

Gene ID Number

6497

Modification Site

None

Tested applications

IF(IHC-P)

French translation

anticorps

Clonality

Polyclonal

Modification

Unmodified

Concentration

1ug per 1ul

Excitation emission

590nm/617nm

Target Antigen

C-SKI/v-SKI

Conjugated with

ALEXA FLUOR® 594

Crossreactivity

Human, Mouse, Rat

Conjugated

Alexa conjugate 1

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Category

Conjugated Primary Antibodies

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-C-SKI/v-SKI PAb ALEXA FLUOR 594

Specificity

This is a highly specific antibody against C-SKI/v-SKI.

Long name

C-SKI/v-SKI Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human C-SKI

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Synonyms

Sloan-kettering viral oncogene homolog; Avian sarcoma viral v ski oncogene homolog; C oncogene; C ski; Ski oncogene; Ski oncoprotein; SKV; v ski avian sarcoma viral oncogene homolog; v ski sarcoma viral oncogene homolog; v-ski sarcoma viral oncogene homolog; SKI_HUMAN.

Background of the antigen

SKI is a nuclear protein that forms homodimers and heterodimers and binds to DNA to function as transcriptional activators and repressors. The SKI oncoprotein dramatically affects cell growth, differentiation, and/or survival. SKI was shown to act in distinct signaling pathways including those involving nuclear receptors, transforming growth factor beta, and tumor suppressors. SKI inhibits transforming growth factor-beta (TGF-beta) signaling through interaction with Smad proteins. SKI represses Smad-mediated transcriptional activation, probably through its action as a transcriptional co-repressor. SKI also inhibits TGF-beta-induced downregulation of genes such as c-myc.